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Introduction {#sec001}
============

The formation of a 4-chambered heart in mammals \[[@pone.0235756.ref001]\] has co-opted mechanisms regulating blood pressure so that many living land mammals including rodents and humans reach a similar level \[[@pone.0235756.ref002]\]. This blood pressure conservation is sustained among differing orders of mammals, despite differences in other physiology characters (e.g. heights, reproductive patterns). The only way this can happen is that basic mechanisms regulating blood pressure (BP) must have been formulated in common ancestors of rodents and humans before 90 million years ago ([www.timetree.org](http://www.timetree.org/)). That was before the human genus existed and before rodents diverged from primate ancestors \[[@pone.0235756.ref003], [@pone.0235756.ref004]\]. Modern humans surfaced only about 300,000 years ago \[[@pone.0235756.ref005]\], and not surprisingly, acquired same mechanisms in controlling BP from primate ancestors in parallel with rodents in an evolutionary tree of mammals \[[@pone.0235756.ref003], [@pone.0235756.ref004]\].

Our practical goal of conducting studies in any organism is to help us understand mechanisms of human hypertension pathogenesis \[[@pone.0235756.ref006]\]. Unknowing which mechanisms are involved in hypertension pathogeneses in general populations, genetic analysis is believed to be unrestrained by known BP physiologies and thus be a promising lead-in towards achieving it \[[@pone.0235756.ref007]\]. Thanks to genome-wide association studies (GWASs) \[[@pone.0235756.ref008]\], detecting human quantitative trait loci (QTLs) for BP became possible. Since then, an incremental gain on an ever-enlarging scale has statistically marked the vicinity of more than 900 BP QTLs by single nucleotide polymorphisms (SNPs) \[[@pone.0235756.ref009]\], even though a statistical association of a SNP is not a proof of its function on BP.

Total variance has been used in quantifying phenotypic variations in heterogeneous human populations. Since only a small fraction of total variance is due to QTLs' impact, and most is due to environmental effects \[[@pone.0235756.ref010]\], the actual magnitude of a physiological effect on BP from a single human QTL could not be known from GWAS. This difficulty is exacerbated by the fact that no human QTLs have been identified to be any component of a physiology system known to affect blood pressure \[[@pone.0235756.ref011], [@pone.0235756.ref012]\]. A physiological difference is obvious between locating a SNP marking a QTL nearby and identifying the QTL itself. Even identified, larger gaps exist between probable triggering pathways initiated by QTLs leading to BP control and known path-physiologies that execute it. Now we are no closer in understanding a pathogenesis for human polygenic hypertension than before the advent of GWASs \[[@pone.0235756.ref013]\]. Further realizing that most GWAS SNPs are located in non-coding regions with unknown functions, we focused on a pivotal question: 'can any of these GWAS SNPs affect blood pressure by function *in vivo*?

Due to experimental advantages using rodent models, mechanisms modulating blood pressure driven by function can be revealed, whereas human studies are limited to epidemiology. Because of conserved mechanisms between rodents and primates, studying BP regulating mechanisms in rodents is equivalent to revealing the same mechanisms in humans, while overcoming unavoidable limitations in human studies.

Recently, we used rodent QTLs as proxies to functionally capture distinct human QTLs \[[@pone.0235756.ref014]\]. 3 rodent BP QTLs resemble 3 specific human GWAS genes. Each of them independently showed a major impact on BP *in vivo*. BP was functionally lowered by normotensive alleles from each of these 3 QTLs, and yet, human GWAS non-coding SNPs do not exist in the rat. Thus, they cannot be involved in the physiological changes in BP caused by these QTLs that have been established before human and rodent ancestors diverged 90 million years ago. These non-coding SNPs are genome insignias earmarking human QTLs nearby, rather than being QTLs themselves. Together, 45 human GWAS genes may fall into 2 epistatic modules /2 common pathways of the BP homeostasis. Thus, QTL modularity explains redundancy of human BP QTLs in collectively controlling BP, and is conserved between rodents and humans.

Nevertheless, this initial work only covered a small section of the rat genome from 21 chromosomes. Here, we aimed at expanding the scope of rat QTL coverage to capture additional human GWAS genes in progressive stages. In the process, our new results have validated the reproducibility of our previous findings. We focused on distinct regions on DSS rat Chromosomes 7 and 8 that contain previously-unexplored rat blood pressure QTLs and human GWAS gene orthologs.

This paper reports results of additional studies in unifying the human and rodent physiology in BP control. (1) We extended functional captures of human QTLs to other genome regions. (2) We grouped these human-relevant QTLs by function into modules. (3) We assessed the functional relevance of GWAS SNPs in BP control, in an *in vivo* model of their natural 'knock outs'. (4) We singled out functional candidates for several QTLs.

Materials & methods {#sec002}
===================

Animals {#sec003}
-------

Animal research has been approved by our institutional committee (CIPA, Comité institutionnel de protection des animaux) with approval number CM19037ADr. Protocols in animal experiments were approved by our institutional animal committee, CIPA. Our basic animal model is inbred hypertensive Dahl salt-sensitive (DSS) rats. Congenic strains were made by replacing distinct chromosome regions of DSS by those of inbred normotensive Lewis rats. Most congenic strains used in the current study are synthesized from our previous work \[[@pone.0235756.ref015]\]. Experimented animals were monitored daily. Euthanasia was done with isofurane at 4% and O2 at 1L/min. The chromosome segment congenically 'knocked in' defines the interval harboring each of multiple QTLs. The chromosome regions containing them are delimited by microsatellite markers.

Experimental protocols and analyses {#sec004}
-----------------------------------

They are the same as documented previously \[[@pone.0235756.ref014], [@pone.0235756.ref015]\]. In brief, male rats were weaned at 21 days after birth, fed on a low-salt diet (0.2% NaCl), then a high-salt diet (2% NaCl) starting at 35 days of age until the experiment was done. Telemetry probes were implanted into the rats of 56 days old. Since systolic and diastolic pressures were consistent with mean arterial pressures (MAP) of all the strains \[[@pone.0235756.ref016], [@pone.0235756.ref017]\], only their MAPs are provided for simplicity. The power and sample size were calculated to be sufficient \[[@pone.0235756.ref018]\].

Repeated measures\' analysis of variance (ANOVA) followed by the Dunnett's test was used to compare the significance in a difference or a lack of it in a blood pressure component between a congenic strain and the DSS parental strain. The Dunnett correction takes into account multiple comparisons as well as sample sizes among the comparing groups. In the analysis, an averaged BP component was compared for each day for the period of measurement among the strains.

Because blood pressures of rats were measured continuously for 2 weeks with one reading at every 2 minutes, the numbers given at the bottom of [Fig 1](#pone.0235756.g001){ref-type="fig"} represent only averaged values of mean arterial pressures for a strain during 2 weeks. A Dunnett value including "\<" given in each comparison between congenic and DSS strains was the most conservative P value among all the days of comparisons.

![Congenic knock in genetics defining BP QTLs *in vivo*.\
A solid bar under congenic strains represents the Dahl salt-sensitive rat chromosome fragment that has been replaced by that of normotensive Lewis rats (S.L). Striped bars on ends of the solid bars denote the ambiguity of crossover breakpoints between markers \[[@pone.0235756.ref015]\]. Full names for abbreviated genes of interest are listed in the footnote for [Table 1](#pone.0235756.t001){ref-type="table"}.](pone.0235756.g001){#pone.0235756.g001}
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###### Identification of human QTLs/GWAS genes from their functional proxy.

![](pone.0235756.t001){#pone.0235756.t001g}

  Rat QTL name          Magnitude of BP effects   Rat Gene              Mutation detected Lew/ DSS                    Change in amino acid (AA) Lew/DSS   Human GWAS SNP                   Rat GWAS SNP ortholog                Closest human GWAS gene   \# probable human missense mutation
  --------------------- ------------------------- --------------------- --------------------------------------------- ----------------------------------- -------------------------------- ------------------------------------ ------------------------- -------------------------------------
  [***C7QTL1***]{.ul}   -41%                      *Nxph4*               A571C                                         T191P                                                                                                     No GWAS gene              13
                                                  *Rdh16 (Rdh2)*        A67G G311C T746C                              M23V R104T M249T                                                                                          No GWAS gene              10
                                                  *Tac3* (*Tac2*)       C162T                                         P55S                                                                                                      No GWAS gene              6
                                                  [***Triobp***]{.ul}   G1491T                                        Q497H                               rs4820296 rs12628603 rs1129448   Non-existent Non-existent Existent   [***TRIOBP***]{.ul}       9
                                                  [***Tnrc6b***]{.ul}   DSS CAG insertion at 3784                     DSS Q insertion (1262)              rs470113                         Non-existent                         [***TNRC6B***]{.ul}       15
  [***C8QTL1***]{.ul}   -41%                      [***Ulk3***]{.ul}     A770G                                         H257R                               rs6495122                        Non-existent                         [***ULK3***]{.ul}         7
                                                  [***Cyp1a2***]{.ul}   G410A T1207C                                  R137H C403R                         rs1378942                        Non-existent                         [***CYP1A2***]{.ul}       16
                                                  *Lman1l*              A64G A809G C1164A                             S22G Q270R H388Q                                                                                          No GWAS gene              17
                                                  [***Ccdc33***]{.ul}   C1108A C2095T                                 P370T R699C                         rs351157 rs4887123 rs94899       All Non-existent                     [***CCDC33***]{.ul}       9
  [***C8QTL2***]{.ul}   +30%                      [***Mtnr1b***]{.ul}   T100C[^†^](#t001fn003){ref-type="table-fn"}   S34P                                rs10830963                       Non-existent                         [***MTNR1B***]{.ul}       15
                                                  [***Snx19***]{.ul}    C430A[\*](#t001fn002){ref-type="table-fn"}    L144M                               rs1050081 rs2276098 rs948086     All Non-existent                     [***SNX19***]{.ul}        18

QTLs are given in [Fig 1](#pone.0235756.g001){ref-type="fig"}.-- or + in magnitude of BP effects in physiology indicates the effect of normotensive alleles for that QTL in decreasing or increasing BP. Genes in bold are QTL candidates for both rats and humans. All missense mutations have been confirmed by independent clonings of the genome segments containing them followed by sequencings.

\* indicates confirmed missense mutations detected in our database and by the public rat genome database.

^**†**^ The mutation showed up in our database only, but has not been confirmed by independent sequencing due to technical difficulties. DSS, Dahl salt-sensitive rat; Lew, Lewis rat. Number of human missense mutations indicates those with minor allele frequency of \>0.04% from exon sequencings. ***Ccd33c*,** coiled-coil domain containing 33; ***Cyp1a2*,** cytochrome P450 family 1 subfamily A member 2; ***Lman1l*,** lectin, mannose binding 1 like; ***Mtnr1b*,** melatonin receptor 1B; ***Nxph4*,** neurexophilin 4; ***Rdh16*,** retinol dehydrogenase 16; ***Snx19*,** sorting nexin 19; ***Tac3*,** tachykinin precursor 3; ***Triobp*,** TRIO and F-actin binding protein; ***Tnrc6b*,** trinucleotide repeat containing adaptor 6B; ***Ulk3*,** unc-51 like kinase 3.

Results {#sec005}
=======

(A) Functional proxy tool and conceptual definitions are as follows {#sec006}
-------------------------------------------------------------------

(a). A congenic strain refers to a homogeneous strain in which a sole chromosome segment from the recipient strain has been replaced by that of the donor strain, while retaining the rest of the genome as that of the recipient. When BP changes as a result, a QTL functionally exists in the replaced segment. In essence, the congenic strategy is similar to that of 'knock-in' \[[@pone.0235756.ref007]\], and is thus termed congenic knock in genetics. In order to visualize physiological effects from BP QTLs, our congenic knock in genetics was done in the DSS genetic background that has lost its genome buffering capacity in tampering BP fluctuations \[[@pone.0235756.ref019]\] and hypertension suppression \[[@pone.0235756.ref018], [@pone.0235756.ref020]\].

(b). Although a QTL is genetically localized to a genome segment containing multiple genes, the molecular basis of 1-gene-for-1 QTL is standardized during QTL identification \[[@pone.0235756.ref007]\]. This has been affirmed by *C17QTL1* as *CHRM3* encoding muscarinic cholinergic receptor 3 (M3R) \[[@pone.0235756.ref014], [@pone.0235756.ref021]\]. No combination is required for *C17QTL1* with any other QTLs to change BP. A missense mutation in *Chrm3* of Dahl salt-sensitive rats (DSS) alters its signaling and was primed for its identity as *C17QTL1*. The functional dosage in M3R signaling, not the *Chrm3* gene dose, determines the degree of hypertension pathogenesis \[[@pone.0235756.ref022]\]. The intergenic GWAS SNP nearby \[[@pone.0235756.ref008]\] is only a marker for the human QTL, not the QTL itself \[[@pone.0235756.ref014]\]. Thus, a 'common' SNP with a set minor allele frequency for human GWAS merely labels a nearby biological QTL that has a 'rare' functional variant. Whether or not the SNP was replicated in other GWAS by statistics \[[@pone.0235756.ref009]\] is irrelevant to its functional impact on BP, because depleting it has no effect on BP \[[@pone.0235756.ref021], [@pone.0235756.ref022]\].

(c). Non-coding human GWAS SNPs \[[@pone.0235756.ref009]\] so far analyzed are by products of primate evolution, since they appeared only in primates not in rodents after they have evolutionarily diverged. This fact indicates that appearances of these SNPs are independent of the establishment of BP regulating mechanisms, which was already fixed before rodents and primates diverged (see introduction). Thus, such a non-coding GWAS SNP cannot be relevant to BP by function \[[@pone.0235756.ref014]\].

The above 3 considerations guide functional discovery of additional BP QTL candidates for humans in following sections. Among all DSS chromosome regions known to harbor BP QTLs \[[@pone.0235756.ref015]\], only those matching human QTL signals from GWAS \[[@pone.0235756.ref009]\] were analyzed here ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}). We begin by functionally defining individual QTLs with human orthologs, followed by grouping them in epistatic modules. We then focused on molecular mechanisms of QTL actions and evaluated the functional impact of human non-coding GWAS SNPs in BP control by proxy.

(B) QTL modularity on BP is functionally conserved between differing mammalian orders {#sec007}
-------------------------------------------------------------------------------------

The BP effect for one gene among hundreds detected in human GWAS \[[@pone.0235756.ref009]\] was calculated as a fraction of total BP variance and seemed miniscule \[[@pone.0235756.ref011]\]. However, the real physiological BP effect of a single QTL by function is considerably larger when viewed in homogeneity, by causality and alone \[details were given in Table 1 in reference \[[@pone.0235756.ref010]\]\].

*C7QTL* on DSS rat Chromosome 7 is a case in point \[[@pone.0235756.ref017]\], and is now re-designated as *C7QTL1* ([Fig 1A](#pone.0235756.g001){ref-type="fig"}). *C7QTL1* was not detected and statistically explained 0% of total variance in an F~2~ population \[[@pone.0235756.ref023]\], yet was capable of functionally altering BP by 41% in the total difference between 2 parental rat strains *in vivo* \[[@pone.0235756.ref017]\]. The calculation is as follows. The congenic knock-in lowered blood pressure by 34 mmHg, or indicated by -34 ([Fig 1A](#pone.0235756.g001){ref-type="fig"}). The total BP difference between DSS and Lewis strains is 83 mmHg, i.e. 178 mmHg for DSS minus 95 mmHg for Lewis. Thus, the blood pressure effect of *C7QTL1* is calculated as -34/83 = -41% (i.e. BP-decreasing effect). By the same calculation, other 3 QTLs, *C7QTL2*, *C8QTL1*, and *C8QTL2*, singularly possess a major physiological BP effect of respective -33%, -41% and +30% (i.e. BP-increasing effect) ([Fig 1](#pone.0235756.g001){ref-type="fig"}, [Table 1](#pone.0235756.t001){ref-type="table"}).

How do these 4 QTLs along with 24 others \[[@pone.0235756.ref021]\] functionally affect BP together *in vivo*? Summing them up cannot be physiological, since that would lower BP to below zero, whereas fractionating each QTL by total variance is not functional. Thus, a valid biological solution is needed on how they together can sustain BP *in vivo*. It turned out that epistatic modularity charts fundamental mechanisms of QTL actions on BP that are functional and physiological \[[@pone.0235756.ref010]\], i.e. their effects on BP are collectively additive only in modularity \[[@pone.0235756.ref015]\].

The *C8QTL1*-residing interval harbors 17 human GWAS genes \[[@pone.0235756.ref009]\] ([Fig 1B](#pone.0235756.g001){ref-type="fig"}) and the *C10QTL1*-residing interval \[[@pone.0235756.ref024]\] bears 3 human GWAS genes \[[@pone.0235756.ref009]\]. When the segment carrying *C8QTL1* was merged with that for *C10QTL1*, their combined BP did not exceed BP for either of them alone \[[@pone.0235756.ref015]\]. This epistasis means one QTL masking the effect of another on BP. Their coexistence in epistasis puts them in the same epistatic module (EM), i.e. EM1 \[[@pone.0235756.ref015]\]. Thus, QTL modularity on BP is conserved between the human GWAS genes and the rodent QTLs that proved their presence by function.

(C) *C8QTL1* of DSS rats functionally corresponds to one of several human GWAS genes \[[@pone.0235756.ref009]\] {#sec008}
---------------------------------------------------------------------------------------------------------------

(**a**) Normotensive alleles of the rodent *C8QTL1* lower BP *in vivo* alone and independently of other QTLs ([Fig 1B](#pone.0235756.g001){ref-type="fig"}). The *C8QTL1*-harboring segment contains a total of 17 human GWAS genes ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}). Among them, 3, and 1 genes respectively can be grouped into 2 genome blocks, according to the existence of functional candidates from DSS rats harboring missense mutations ([Fig 1B](#pone.0235756.g001){ref-type="fig"} and [Table 1](#pone.0235756.t001){ref-type="table"}). 2 intergenic GWAS SNPs, rs1378942 and rs6495122, define block 1, and several intronic SNPs mark block 2 ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}). A distance of 423 kb separates block 1 from block 2 ([Fig 1B](#pone.0235756.g001){ref-type="fig"}) and implies 2 distinct QTLs in the region now defined to contain *C8QTL1*. To confirm this, further evidence of fine resolution by congenic knock in genetics \[[@pone.0235756.ref021]\] will be needed to trap each block and to isolate it from one another by function.

Regardless, both human GWAS and *in vivo* rodent studies converge to prove that one or several of GWAS signals statistically associated with BP may be capable of functionally altering BP. Conversely, *C8QTL1* has extended to humans beyond the confines of rodents, and functionally changed BP in a magnitude of 41% ([Table 1](#pone.0235756.t001){ref-type="table"}) in the total difference between 2 contrasting parental strains. This is evident despite that how many human GWAS genes corresponding to how many rodent QTLs remain unresolved in the *C8QTL1*-residing region, which is still large ([Fig 1B](#pone.0235756.g001){ref-type="fig"}).

(**b**) Next, we examined the molecular basis that prioritize 5 functional candidates for the 2 blocks containing human GWAS genes ([Fig 1B](#pone.0235756.g001){ref-type="fig"}, [Table 1](#pone.0235756.t001){ref-type="table"}). If one or some of these inter-and intronic GWAS SNPs would affect BP *in vivo*, they should exist in congenic strain C8S.L1 which served a functional proxy for human GWAS genes, since BP was lowered by normotensive *C8QTL1* alleles ([Fig 1B](#pone.0235756.g001){ref-type="fig"}). We first searched all these GWAS SNPs and no similar sequences were detected in the rat genome ([S2 Table](#pone.0235756.s003){ref-type="supplementary-material"}). No homologies were found for the mouse genome. The absence of these SNPs is not due to a possible anomaly in rat genome assembly. These SNPs and surrounding non-coding sequences are not conserved in rodents. The genome regions around the intergenic and intronic SNPs are not known to play a regulatory role in gene expressions.

Since the physiological change in BP occurred *in vivo* ([Fig 1B](#pone.0235756.g001){ref-type="fig"}), when these SNPs are naturally 'knocked out', the SNPs themselves cannot be responsible for altering BP by *C8QTL1*, and appears solely as a marker for the functional QTL nearby, not the QTL *per se*. This conclusion was further strengthened by the fact that these SNPs are by-products of primate evolution, rather than a demand in functionally controlling BP. These SNPs emerged only in certain simians and apes ([S3 Table](#pone.0235756.s004){ref-type="supplementary-material"}), long after primates and rodents have diverged, and long after BP-regulating mechanisms common between primates and rodents were already set and remained little changed since.

(**c**) We reasoned that physiologically, valid candidate genes have to be both conserved between the rat and humans as well as capable of potentially altering BP by function. The coding domains of five genes fulfils these 2 criteria. In block 1 ([Fig 1B](#pone.0235756.g001){ref-type="fig"}), *Ulk3*, *Cyp1a2*, and *Lman1l* are close to one another ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}), and carry missense mutations, which were first detected in both our genome data base \[[@pone.0235756.ref025]\] and the public rat genome data base (RGD) \[[@pone.0235756.ref026]\] ([Table 1](#pone.0235756.t001){ref-type="table"}). We then individually cloned and sequenced all the exons and intron-exon junctions of the 3 genes. The same missense mutations were then confirmed to alter their protein structures and may have a functional impact. Thus, their coding structures are strongest functional candidates for corresponding 3 human GWAS genes.

We next searched human coding domain data bases \[[@pone.0235756.ref027]\], and found 7, 16 and 7 missense mutations in human *ULK3*, *CYP1A2*, and *LMAN1L* respectively ([S4 Table](#pone.0235756.s005){ref-type="supplementary-material"}). Although the same missense mutations were not found in humans as in rats, various missense mutations throughout their protein structures might have functional implications.

(**d**) One functional candidate was found for block 2 in the *C8QTL1*-residing interval ([Fig 1B](#pone.0235756.g001){ref-type="fig"}), because *Ccdc33* contains missense mutations in both rats ([Table 1](#pone.0235756.t001){ref-type="table"}) and humans ([S4 Table](#pone.0235756.s005){ref-type="supplementary-material"}). In contrast, the intronic GWAS SNPs in *CCDC33* ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}) only exist in humans and other primates ([S3 Table](#pone.0235756.s004){ref-type="supplementary-material"}), but are 'knocked out' in rodents ([S2 Table](#pone.0235756.s003){ref-type="supplementary-material"}). Once again, these non-coding GWAS SNPs can only be markers for the potential QTL nearby, but are not QTL *per se*, because genome domains determining BP-controlling mechanisms should be common between rodents and humans.

(D) *C8QTL2* of DSS rats functionally captures human GWAS genes \[[@pone.0235756.ref009]\] {#sec009}
------------------------------------------------------------------------------------------

(**a**) In contrast to *C8QTL1*, normotensive alleles of *C8QTL2* raise BP *in vivo* by +30% in the difference between 2 parental strains ([Fig 1B](#pone.0235756.g001){ref-type="fig"}, [Table 1](#pone.0235756.t001){ref-type="table"}). Among 11 human GWAS genes in the *C8QTL2*-residing region ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}), 2 of them can be in 2 genome blocks separated by a 17 Mb gap and correspond to 2 functional candidates from rodents carrying missense mutations ([Fig 1B](#pone.0235756.g001){ref-type="fig"} and [Table 1](#pone.0235756.t001){ref-type="table"}). This implies 2 distinct QTLs in the broad region presently defined to contain *C8QTL2*. This functional evidence has united at least one of human GWAS genes and rodent *C8QTL2*, beyond an overall similarity in BP between the 2 orders of mammals.

(**b**) We next prioritized functional candidate genes based on the existence of missense mutations in them. *Mtnr1b* and *Snx19* coding domains bear the same missense mutations ([Table 1](#pone.0235756.t001){ref-type="table"}) in our rat data base \[[@pone.0235756.ref025]\] and RGD \[[@pone.0235756.ref026]\], although we have not singularly cloned and sequenced all their exons. Coding regions of human *MTNR1B* and *SNX19* are highly conserved with those of rats and contain various missense mutations ([S4 Table](#pone.0235756.s005){ref-type="supplementary-material"}). Rat orthologs for remaining 9 GWAS genes in the *C8QTL2*-residing interval ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}) do not carry missense mutations and thus are not prioritized as functional candidates.

In contrast to the conserved coding domains in *MTNR1B* and *SNX19* between rats and humans, non-coding GWAS SNPs marking them only exist in primates including humans ([S3 Table](#pone.0235756.s004){ref-type="supplementary-material"}), but are 'knocked out' in rodents ([S2 Table](#pone.0235756.s003){ref-type="supplementary-material"}). Since BP changed by congenic knock in genetics independently of them, they cannot be responsible for the functionality of *C8QTL2*, because genome domains regulating BP should be shared in both rodents and humans.

(E) *C7QTL1* of DSS rats may belong to a functional human ortholog of GWAS genes \[[@pone.0235756.ref009]\] {#sec010}
-----------------------------------------------------------------------------------------------------------

(**a**) Normotensive alleles of *C7QTL1* lower BP *in vivo* ([Fig 1A](#pone.0235756.g001){ref-type="fig"}). Among 21 human GWAS genes in the *C7QTL1*-residing region ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}), 2 of them can be in 2 genome blocks separated by a 1.7 Mb gap ([Fig 1B](#pone.0235756.g001){ref-type="fig"} and [Table 1](#pone.0235756.t001){ref-type="table"}). This implies 2 isolated QTLs in the broad region presently known to contain one QTL, *C7QTL1*. This functional evidence has unified, at minimum, one of human GWAS genes and the rodent *C7QTL1*.

(**b**) We next identified potential functional candidate genes based on the existence of missense mutations in them. *Triobp* and *Tnrc6b* coding domains bear missense mutations ([Table 1](#pone.0235756.t001){ref-type="table"}) based on our rat data base \[[@pone.0235756.ref025]\] and RGD \[[@pone.0235756.ref026]\]. We then cloned and sequenced the exons suspected to contain the missense mutations. These mutations are confirmed ([Table 1](#pone.0235756.t001){ref-type="table"}). Rat orthologs for remaining 19 GWAS genes in the *C7QTL*-residing interval ([S1 Table](#pone.0235756.s002){ref-type="supplementary-material"}) do not carry missense mutations and thus are not prioritized as functional candidates at this point.

In contrast to the conserved coding domains between rat and humans, non-coding GWAS SNPs marking them only exist in primates including humans ([S3 Table](#pone.0235756.s004){ref-type="supplementary-material"}), but are 'knocked out' in rodents ([S2 Table](#pone.0235756.s003){ref-type="supplementary-material"}). Since BP changed by congenic knock in genetics without them, they cannot be responsible for the function of *C7QTL1*, because of conserved BP-modulating mechanisms between rats and humans.

Discussion {#sec011}
==========

Primary findings from this work are (**a**) *in vivo* studies and human GWAS have begun to consolidate mechanisms of BP control into a biological framework for a quantitative and polygenic trait. QTL modularity on BP is conserved between divergent mammalian orders such as rodents and humans ([www.timetree.org](http://www.timetree.org/)). (**b**) As a proof of principle, 3 distinct QTLs from inbred DSS rats have functionally captured at least 3 human GWAS genes. Each of them has a major physiological impact on BP. (**c**) The non-coding SNPs marking these 3 QTLs/human GWAS genes are spin-offs of primate evolution autonomously of BP regulation. They mark potential QTLs nearby, rather than QTLs themselves.

QTL Modularity/non-cumulativity explains not only physiological controls on BP but also their evolutionary conservation {#sec012}
-----------------------------------------------------------------------------------------------------------------------

A BP effect for a given GWAS signal in a general population seemed miniscule as it is often fractionated from total BP variance \[[@pone.0235756.ref009]\]. Total variance gauges a spread of BP in the heterogeneous populations and largely due to environments, not due to QTLs. Since environmental factors are not inherited, the often-referred to 'missing' heritability for BP is not physiologically mechanistic. Missing total variance is not the same as 'missing' heritability. In physiological reality, each of the 3 QTLs of human orthologs alone showed a major effect on BP by function, although BP effects for many more GWAS genes are not known due to a lack of fine resolution from congenic knock ins ([Fig 1](#pone.0235756.g001){ref-type="fig"}). Thus, a pertinent functional issue to address is how they can collectively impact on BP, in spite of their functional redundancy.

Several human GWAS genes may be grouped into only 2 epistatic modules by their functions together in physiologically controlling BP. This insight implicates 2 pathways of hypertension pathogeneses and one of them is the M3R signaling pathway \[[@pone.0235756.ref021]\]. Thus, QTL modularity on BP is conserved between differing orders of mammals as divergent as humans and rodents and proves in principle that physiological pathways regulating BP are shared between humans and rodents.

Since the physiological system of BP control in mammals including rodents and humans has not changed before and since their evolutionary divergence \[[@pone.0235756.ref002]\], the occurrence of non-coding SNPs uniquely in humans is a coincidence in primate evolution. Such a non-coding GWAS SNP marks the position of a functional QTL nearby, similar to the microsatellite polymorphism \[[@pone.0235756.ref028]\] signalling *C17QTL1*/*Chrm3* next to it \[[@pone.0235756.ref021]\]. Thus, replicating such a GWAS SNP is an epidemiological exercise independently of identifying the QTL next to it that actually affects blood pressure, but carries less prevalent missense mutations.

Mechanistic and physiological insights into controlling blood pressure as a polygenic trait from QTL modularity {#sec013}
---------------------------------------------------------------------------------------------------------------

The modularity of QTLs \[[@pone.0235756.ref010], [@pone.0235756.ref015]\] has enlarged the coverage of Mendelism, added a new physiological dimension to polygenic trait genetics, and provided a mechanistic framework for how redundant QTLs act together in regulating mammalian BP including those in humans.

Lately, an 'omnigenic' hypothesis has been expressed to cover GWAS results on various phenotypes including blood pressure \[[@pone.0235756.ref013]\]. It can even be referred to as an anthropocentric (or human-centered) hypothesis, because non-coding SNPs used in GWAS only exist in humans, not in rodents. It essentially suggests that it is regulations at gene expressions that determine the GWAS SNPs' roles in any phenotypes including BP in humans, contrary to the modularity paradigm \[[@pone.0235756.ref010], [@pone.0235756.ref015]\].

The basic difference between the two is that the modularity concept is based on the functional physiology with verifiable pathogenic mechanisms of hypertension versus statistical epidemiology without a functional physiology and mechanisms. This is because mechanisms and physiology determining a polygenic trait are only an afterthought, not the initial driving force or the starting point in the omnigenic model. These 2 conflicting hypotheses produce different predictions that can be experimentally tested for their physiological relevance on BP. From the perspective of functional physiology in blood pressure regulation, modularity is supportive, but omnigenicity is not, because of the following.

(a). A gene dose, and by inference, the level of gene expressions are central to the 'omnigenic' hypothesis. However, several lines of experimental evidence have proven that a gene dose is irrelevant to the physiological impact on the hypertension pathogenesis. For example, *Chrm3*^*+/-*^ has only one functional copy of *Chrm3* and *Chrm3*^*+/+*^ has 2 copies. Despite this difference in gene copies, blood pressures of both genotypes are the same \[[@pone.0235756.ref021], [@pone.0235756.ref022]\]. Multiple QTLs behave in this gene-dose independence in the functional physiology of BP control \[[@pone.0235756.ref029]\].

(b). The infinitesimal effect from a single QTL marked by a GWAS SNP is predicted from the 'omnigenic' hypothesis along with a phenotypic gradient in response to the dose of QTLs. If this assumption were physiologically relevant, depleting one such QTL should have a trivial effect on BP. This is not the case. Depleting *Chrm3* alone causes BP to drop more than 50% comparing the full-body *Chrm3*^*-/-*^ with *Chrm3*^*+/+*^ \[[@pone.0235756.ref021]\]. Not only that, BP diminished sharply (e.g. 28%) when normotensive alleles of *Chrm3* is knocked in to the background of hypertensive DSS rats \[[@pone.0235756.ref021]\].

(c). QTL modularity explains redundancy of human BP QTLs in collectively controlling BP, and a non-cumulative correspondence between QTL numbers and BP effects. Adding more QTL alleles from another epistatic module changed blood pressure in a 'leap', not in a gradual gradient and not in proportion \[[@pone.0235756.ref015]\]. The 'omnigenic' hypothesis predicted the opposite.

(d). The modularity concept can, whereas the 'omnigenic' hypothesis cannot, support the evolutionary conservation in modules/pathways controlling BP between rodents and humans that are separated in time by 90 million years ([timetree.org](http://timetree.org)). The non-coding GWAS SNPs marking human QTLs only began to appear in primates, but do not exist in rodents with whom humans shared same BP-regulating mechanisms. Thus, it is the functional impact of Chrm3 signaling that determines the hypertension pathogenesis, not any of the non-coding rodent SNPs around the Chrm3 codons and the non-existent human GWAS SNP. This is because knocking out the Chrm3 signaling did not touch any of these rodent SNPs, yet BP changed. The Chrm3 signaling is conserved between humans and rodents.

Thus, the human BP physiology is not peculiarly different from that of rodents, nor is it more complicated. It's simply more difficult to dissect and distinguish than that of inbred rodents due to experimental limitations on revealing pathogenic mechanisms by function. In the vast scheme of mammalian BP-regulating mechanisms, rodents and humans are simply tiny branches on an evolutionary tree supported by a central mammalian 'trunk'.

(e). The involvement of certain QTLs \[[@pone.0235756.ref021]\] starts at embryogenesis, before the onset of adult BP physiology. The 'omnigenic hypothesis' does not seem to explain how 'regulations at gene expressions' at embryogenesis could affect adult BP. In contrast, the modularity concept explains that a pathway is involved in BP control and a pathway can temporally begin at embryogenesis \[[@pone.0235756.ref021]\].

(f). In summary, the QTL modularity concept is supported by uncontested physiological evidence as a signaling pathway, and is broader and more profound in our understandings of mechanisms of BP control than the 'omnigenic' hypothesis, which has little functional support for any physiological role on BP.

Dissociating 'common' GWAS non-coding variants from closely-linked 'rare' coding mutations {#sec014}
------------------------------------------------------------------------------------------

Natural 'knock outs' of non-coding GWAS SNPs in our current work showed that they do not have a physiological impact on blood pressure. They might potentially have functions in modulating gene expressions, epigenetics and/or even be eQTLs, but they are not involved in physiological regulations of BP in mammals including humans.

The use of GWAS is, nonetheless, useful in labeling the vicinity of functional QTLs close by \[[@pone.0235756.ref009]\]. We have discussed in depth the issue of a marker being separable from a functional QTL next to it, and the ambiguity of statistical confidence interval in the LD application in our previous publication \[[@pone.0235756.ref014]\]. This topic will not be repeated here.

Statistical incertitude may lead to a detected signal for a QTL being false negative or false positive \[[@pone.0235756.ref007]\], to which a SNP's prevalence is immaterial. A proof by function is the only yardstick in assessing it. Not detecting *C7QTL1* and *C7QTL2* is an example of statistical false negativity \[[@pone.0235756.ref023]\] and was rectified only by a functional proof in changing BP in congenic knock in genetics ([Fig 1A](#pone.0235756.g001){ref-type="fig"}). A lack of functional impact on BP proved that a statistical detection of a QTL near *inducible nitric oxide synthase* was false positive \[[@pone.0235756.ref030]\].

Dissociation of blood pressure with vaso-dilation mediated by M3R encoded by *Chrm3* {#sec015}
------------------------------------------------------------------------------------

Recently, an endothelial cell-targeted *Chrm3* knock out in mice showed that blood pressure was not affected \[[@pone.0235756.ref031]\]. Their results are consistent with those in the full-body knockout of *Chrm3* of rat and mice in that vasodilation mediated by M3R is diminished \[[@pone.0235756.ref021], [@pone.0235756.ref032]\]. Despite an impaired vasodilation, blood pressure in our full-body *Chrm3* knock out rats was lowered, not raised \[[@pone.0235756.ref021]\]. This paradox has created a physiological puzzle \[[@pone.0235756.ref033]\] that blood pressure is not regulated by vasodilation *per se* mediated by the M3R-mediated signaling.

This separation suggests the following in the genetics of hypertension in either humans or animal models. Unknowing a precise mechanism in blood pressure regulation, the pivotal starting point in proving a QTL has to be its functional impact on blood pressure itself *in vivo*. Any 'intermediate phenotype' connected to blood pressure control cannot substitute this indispensable functional proof. This proof will then drive our mechanistic understandings of the gene, irrespective of our intuitive and known ideas on how blood pressure regulations should be mediated. This function-mechanism consideration can be extrapolated to any other quantitative and polygenic trait in addition to blood pressure, especially when obtained from GWAS.

Concerning M3R, 'the absence of M3R does not mean an endothelial dysfunction, only that the M3R-mediated pathway is inactivated. Many M3R-independent pathways in the endothelium remain active and likely important for BP regulation. Since BP decreases *in vivo* in the (full-body) *Chrm3*-nulls, even if endothelium-derived acetylcholine could contribute to endothelium-dependent dilation, it is likely to be compensated *in vivo* by other mechanisms such as improved renal and cardiac activities' \[[@pone.0235756.ref022]\].

Pathogenic pathways of hypertension inferred from the molecular bases of QTLs {#sec016}
-----------------------------------------------------------------------------

Since the 4 QTLs in questions ([Fig 1](#pone.0235756.g001){ref-type="fig"}) have not been molecularly identified, their roles in BP control are tentative and inferred only from the functional candidate genes with missense mutations representing them.

In epistatic module 2/pathway 2 as muscarinic cholinergic receptor 3 \[[@pone.0235756.ref021], [@pone.0235756.ref022]\], MTNR1B is a G-protein-coupled melatonin receptor primarily expressed in the brain retina. Knocking it out showed no detectable phenotype \[[@pone.0235756.ref034]\], although blood pressure was not measured SNX19 seems to function in pancreatic β cells \[[@pone.0235756.ref035]\] and ubiquitously expressed \[[@pone.0235756.ref036]\].

In epistatic module 1/pathway 1, 3 functional candidate genes, *Ulk3*, *Cyp1a2*, and *Lman1l*, are present in block 1 in the *C8QTL1*-lodging region ([Fig 1B](#pone.0235756.g001){ref-type="fig"}). ULK3 is a serine/threonine kinase involved in embryonic hedgehog pathway \[[@pone.0235756.ref037]\], although its tissue distribution is mostly in skin and small intestine. *CYP1A2* is a cytochrome P450 enzyme specifically expressed in liver \[[@pone.0235756.ref038]\] and involved in eliminating exogenous chemicals. LMAN1l is a mannose-binding and lectin-like protein involved in organelle trafficking \[[@pone.0235756.ref039]\] and primarily expressed in prostate \[[@pone.0235756.ref040]\]. A siRNA delivery of *Ulk3* or *Cyp1a2* did not alter blood pressure \[[@pone.0235756.ref041]\]. *Lman1l* was included in a mouse knock out library \[[@pone.0235756.ref042]\], but no phenotype was detailed. *Cyp1a2* null mice showed a deficient drug metabolism \[[@pone.0235756.ref038]\]. *CCDC33* is primarily expressed in testes \[[@pone.0235756.ref043]\], and appeared to be not vital for development \[[@pone.0235756.ref044]\]. TRIOBP controls cytoskeleton organization and is involved in hearing \[[@pone.0235756.ref045]\]. Tnrc6b is a protein with repeated glycine/tryptophan residues, may play a role in gene silencing by small interfering-RNAs and microRNAs, and is semi-required for development \[[@pone.0235756.ref046]\].

Caveats and limitations {#sec017}
-----------------------

First, although human GWAS genes with missense mutations do not genetically prove by themselves to be the QTLs in questions, they provide entry points towards probable pathways underlying the function of each QTL. They are molecular targets for designing viable gene-specific experiments in validating their functions on blood pressure. Unlike non-existence of non-coding GWAS SNPs ([S2 Table](#pone.0235756.s003){ref-type="supplementary-material"}), the coding mutations can be tested in rodents by function.

Second, structural mutations are not necessarily the only molecular bases that can affect a pathway in question. Although bearing no missense mutation, *CSK* encodes a c-src tyrosine kinase, is located between *Cyp1a2* and *Lman1l* and a candidate gene for a QTL. A *Csk* knock down and *Csk*^*+/-*^ showed a decrease in blood pressure \[[@pone.0235756.ref041]\]. This directionality is the opposite of what expected from the human non-coding GWAS SNP, rs1378942 \[[@pone.0235756.ref009]\], which is naturally 'knocked out' in mice and had no effect on BP \[[@pone.0235756.ref041]\].

*Atp2b1* in the *C7QTL2*-residing interval ([Fig 1A](#pone.0235756.g001){ref-type="fig"}) carries no missense mutation. However, an *Atp2b1* knock down has shown an increase in blood pressure \[[@pone.0235756.ref047]\]. A vascular smooth muscle-targeted *Atp2b1* knock out showed an increase in blood pressure \[[@pone.0235756.ref048]\] as well as in heterozygotes of a full-body knock out \[[@pone.0235756.ref049]\]. The fact that *Atp1b1* and *Csk* nulls are not viable indicates that their functional involvement in BP control may begin in embryogenesis \[[@pone.0235756.ref050]\].

In conclusion, both *in vivo* rodent studies and human GWAS have revealed common QTLs. Each of them has a major functional impact on BP, even though non-coding GWAS SNPs next to them have no such functional effects. Missense mutations of specific genes qualify them to be functional candidates for certain QTLs. The shared epistatic modularity among human and rodent QTLs suggests that they may function in a common pathway evolutionarily conserved, and each is involved in a different step in the pathogenic pathway for polygenic hypertension.

Supporting information {#sec018}
======================

###### ARRIVE guidelines checklist.

(PDF)

###### 

Click here for additional data file.

###### Rat QTLs and genes.

(DOCX)

###### 

Click here for additional data file.

###### A survey of sequence homologies between humans and the rats for non-coding GWAS SNPs.

(DOCX)

###### 

Click here for additional data file.

###### Survey of non-coding GWAS SNP conservations/homology during primate evolution.

(DOCX)

###### 

Click here for additional data file.

###### Coding mutation alignments for rat and human genes.

(DOCX)

###### 

Click here for additional data file.
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Deng & Menard seek to publish a follow-up study on the genetic underpinnings of hypertension that builds from their recently published work (e.g., Deng & Menard, PMID: 31584514). In particular, the authors are seeking to reconcile findings of human epidemiology with genetic mechanisms of rodent models with tools that utilize a modularity (vs. an "omnigenic" regulation) approach. The manuscript demonstrates knowledge of the nuances involved in using respective hypertension models (humans vs. rats) and interpretation of the resulting data thereof. Also, they endeavor to harness scientific reductionism in their general approach (e.g., rat to human orthologs) to help open up more paths of translation towards effective blood pressure control in human subjects. See my comments below.
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\(2\) General: The authors could improve the manuscript throughout by considering and providing more of a balanced discussion of their findings in light of the literature. Also, as appropriate for scientific efforts and reports, statements of data should be limited to being supportive or suggestive of their conclusions rather than the only "right" or "valid" answer(s) vs. the broader peer-reviewed literature.

\(3\) General: Toggling various genes on and off or mutating them in a global manner with fortuitous consequences on blood pressure does not necessarily illuminate their individual (or interactive) roles in the grand scheme of blood pressure control or make them practical for understanding/treating hypertension. As an example, Chrm3 deletion specific to endothelial cells (a cell type central to determining vascular resistance and thus, blood pressure) does not appear to significantly alter peripheral vascular resistance, arterial tone, arterial blood pressure, or cardiac function (Rhoden et al 2019, PMID: 30716211). In tandem, this same study reported that the Chrm3 endothelium-specific knockout animal also contained reduced expression of mRNA transcripts for isoforms 1, 2, 4, & 5 (1, 3, 5 are Gq-type and 2 & 4 are Gi-type) by \>40% in a vascular endothelium specific knockout of Chrm3 vs. wild-type. The potential for heteromeric interaction among isoforms as integral membrane proteins can not be excluded either. Again, no one study makes for a complete "right" answer but well-evidenced possibilities (and other layers of regulation supporting physiological function) outside of and/or complementary to the authors' approaches and hypotheses should be considered as well.

\(4\) Although published previously, the authors should still at least define and specify animal models (DSS, biological sex, etc.) up front in the Animals section of Materials and Methods.

Reviewer \#2: The authors have proposed an extension of their previous studies \[15\]\[16\] to PLoS ONE. Since it is an extension, careful content delineation from the previous studies is expected. Unfortunately, it appears to me that the extension is weak and vague. I do not see any novel or sound insight into the study.

1\. Statistical analyses were not rigorously performed in the study.
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3\. The insights into BP are vague and speculative.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Reviewer \#1: Deng & Menard seek to publish a follow-up study on the genetic underpinnings of hypertension that builds from their recently published work (e.g., Deng & Menard, PMID: 31584514). In particular, the authors are seeking to reconcile findings of human epidemiology with genetic mechanisms of rodent models with tools that utilize a modularity (vs. an "omnigenic" regulation) approach. The manuscript demonstrates knowledge of the nuances involved in using respective hypertension models (humans vs. rats) and interpretation of the resulting data thereof. Also, they endeavor to harness scientific reductionism in their general approach (e.g., rat to human orthologs) to help open up more paths of translation towards effective blood pressure control in human subjects. See my comments below.

Response to Reviewer \#1 summary comment: Your summary is to the point. We agree.

\(1\) General: As presented, it is not readily apparent that this manuscript is a significantly new and distinguished contribution relative to previous efforts (e.g., Deng & Menard 2019, PMID: 31584514). Although objectives/accomplishments are listed (Introduction, Lines 86-90), there needs to be a more clearly presented case for unfulfilled questions left over from previous efforts and how this study addressed them.

Response to Reviewer \#1 comment (1): You are right. We have added a section in the introduction to present unfulfilled questions left over and how the current study planned to address them as follows.

Nevertheless, this initial work only covered a small section of the genome. Other rat chromosome regions that contain orthologs of human GWAS genes have not been studied.

\(2\) General: The authors could improve the manuscript throughout by considering and providing more of a balanced discussion of their findings in light of the literature. Also, as appropriate for scientific efforts and reports, statements of data should be limited to being supportive or suggestive of their conclusions rather than the only "right" or "valid" answer(s) vs. the broader peer-reviewed literature.

Response to Reviewer \#1 comment (2): Thanks for pointing out the latest publication by Rhoden et al 2019, PMID: 30716211. In discussions, the results from this paper have been discussed to balance our results. A broader peer-reviewed literature is mostly presented in the Introduction. We have tried to tone down statements as you recommended throughout the manuscript as much as we can.

\(3\) General: Toggling various genes on and off or mutating them in a global manner with fortuitous consequences on blood pressure does not necessarily illuminate their individual (or interactive) roles in the grand scheme of blood pressure control or make them practical for understanding/treating hypertension. As an example, Chrm3 deletion specific to endothelial cells (a cell type central to determining vascular resistance and thus, blood pressure) does not appear to significantly alter peripheral vascular resistance, arterial tone, arterial blood pressure, or cardiac function (Rhoden et al 2019, PMID: 30716211). In tandem, this same study reported that the Chrm3 endothelium-specific knockout animal also contained reduced expression of mRNA transcripts for isoforms 1, 2, 4, & 5 (1, 3, 5 are Gq-type and 2 & 4 are Gi-type) by \>40% in a vascular endothelium specific knockout of Chrm3 vs. wild-type. The potential for heteromeric interaction among isoforms as integral membrane proteins can not be excluded either. Again, no one study makes for a complete "right" answer but well-evidenced possibilities (and other layers of regulation supporting physiological function) outside of and/or complementary to the authors' approaches and hypotheses should be considered as well.

Response to Reviewer \#1 comment (3): We'd like to thank you again for pointing out the last publication on a Chrm3 conditional knock out (Rhoden et al 2019, PMID: 30716211). Their results are consistent with those in our full-body knockout of Chrm3 in that vasodilation mediated by its protein product is diminished, and acts independently of blood pressure control.

Despite an impaired vasodilation, blood pressure in our full-body Chrm3 knock out was lowered, not raised (Deng et al 2018, PMID: 30354759), whereas depleting Chrm3 from endothelial cells by Rhoden and coworkers did not change blood pressure. This paradox has created a physiological puzzle (Cowley 2018, PMID: 30354773). That means that blood pressure is not regulated by vasodilation per se mediated by the Chrm3-mediated pathway in the endothelial cells.

This separation suggests the following in the genetics of hypertension in either humans or animal models. Unknowing a precise mechanism in blood pressure regulation, the pivotal starting point in proving a QTL has to be its functional impact on blood pressure itself in vivo. Any 'intermediate phenotype' connected to blood pressure control cannot substitute this indispensable functional proof. This proof will then drive our mechanistic understandings of the gene, irrespective of our intuitive and known ideas on how blood pressure regulations should be mediated. This function-mechanism consideration can be extrapolated to any other quantitative and polygenic trait in addition to blood pressure, especially on GWAS.

Concerning Chrm3 encoding M3R, it is further discussed in (Deng et al 2019, 10.1016/j.cjca.2018.12.029'). 'The hypertension pathophysiology directed by M3R is largely dissociated from the M3R-mediated vaso-relaxation. However, the absence of M3R does not mean an endothelial dysfunction, only that the M3R-mediated pathway is inactivated. Many M3R-independent pathways in the endothelium remain active and likely important for BP regulation. Since BP decreases in vivo in the (full-body) Chrm3-nulls, even if endothelium-derived acetylcholine could contribute to endothelium-dependent dilation, it is likely to be compensated in vivo by other mechanisms such as improved renal and cardiac activities'.

A new section has been added in the Discussion.

\(4\) Although published previously, the authors should still at least define and specify animal models (DSS, biological sex, etc.) up front in the Animals section of Materials and Methods.

Response to Reviewer \#1 comment (4): We agree with you. Some information as you requested has been added. Our basic animal model is inbred Dahl salt-sensitive (DSS) rats. Congenic strains were made by replacing distinct chromosome regions of DSS by those of inbred normotensive rats.

Reviewer \#2: The authors have proposed an extension of their previous studies \[15\]\[16\] to PLoS ONE. Since it is an extension, careful content delineation from the previous studies is expected. Unfortunately, it appears to me that the extension is weak and vague. I do not see any novel or sound insight into the study.

Response to Reviewer \#2 general comment: We have delineated novelty in the revision. Our first-phase studies were limited to a few rat QTLs of human GWAS orthologs. They provided a proof of principle study. However, there are a lot more rat QTLs that correspond to additional human GWAS genes. We are reporting our studies on them here in this manuscript.

A sentence was added to the beginning of last section in Introduction as follows:

'Nevertheless, this initial work only covered a small section of the genome. Other rat chromosome regions that contain orthologs of human GWAS genes have not been studied'. We hope now the novelty is clearer than our previous version.

1\. Statistical analyses were not rigorously performed in the study.

Response to Reviewer \#2 comment (1): Our statistical analyses have been reported extensively in our previous studies. We did not put them in our original submission to Plos One. Now in addressing your concerns, we have added statistics to the end of Material and Method section as follows:

Repeated measures\' analysis of variance (ANOVA) followed by the Dunnett's test was used to compare the significance in a difference or a lack of it in a blood pressure component between a congenic strain and the DSS parental strain. The Dunnett correction takes into account multiple comparisons as well as sample sizes among the comparing groups. In the analysis, a BP

component was compared on each day for the period of measurement among the strains.

Because blood pressures of rats were measured continuously for 2 weeks with one reading at every 2 minutes, the numbers given at the bottom of Fig. 1 represent only averaged values of mean arterial pressures for a strain during 2 weeks. A Dunnett value including "\<" given in each comparison between congenic and DSS strains was the most conservative P value among all the days of comparisons.

In case that you may suggest a genome-wide statistics, it's not relevant to comparing a congenic trait with the DSS parental rats.

2\. There is not any new data or algorithm in the study.

Response to Reviewer \#2 comment (2): Please see our responses to your comment (1) above.

3\. The insights into BP are vague and speculative.

Response to Reviewer \#2 comment (3): In our current study, we have provided the physiological evidence, for the first time, that certain human GWAS genes functionally affect blood pressure by rat QTL proxies. As you may know, GWAS results are probabilistic and statistical. No functional data can be obtained regarding the blood pressure physiology. The next phase of studies will be to molecularly identify the QTL/human GWAS gene that is involved in hypertension pathogenesis. Mechanistic insights will follow. We suppose what you meant by 'vague and speculative' is that a specific gene has not been molecularly identified to be responsible for hypertension pathogenesis. These are limitations of current studies that are recognized in Caveats and limitations section of the manuscript.

4\. The writing is pretty confusing with lots of specific but unnecessary terminologies.

Response to Reviewer \#2 comment (4): We attempted at minimizing specific terminologies in the revision. However, some terminologies are necessary to convey the scientific message, such as congenic strains, congenic knock in genetics, GWAS, SNPs, QTLs, and gene names CSK etc.

see cover letter for more
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Conserved mammalian modularity of quantitative trait loci revealed human functional orthologs in blood pressure control

PLOS ONE

Dear Dr. Deng,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The Reviewers of the previous round were in total disagreement in their assessments, so I needed to involve two additional reviewers, whose evaluation is somehow positive but not sufficiently deep in some points. One first-stage reviewer, indeed, found that your reviewing effort at the previous round was insufficient.

The main issue to be addressed is the novelty of this contribution with respect to the previous work by the authors, in particular the recent paper \[14\], with which the discussion has much overlap. Furthermore, please check and update references and address all the remaining concerns according to the Reviewers\' comments.

We would appreciate receiving your revised manuscript by Jun 15 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Alessandro Borri

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: (No Response)

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: (No Response)

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: (No Response)

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: TO THE AUTHORS:

PLOS One; PONE-D-19-35461.R1

Title: Conserved mammalian modularity of quantitative trait loci revealed human functional orthologs in blood pressure control

Although some of my concerns have been sufficiently addressed while bringing up exciting questions for further study (regulation of endothelial-dependent vascular tone vs. regulation of systemic blood pressure), the revised presentation of the original manuscript appears to be a very modest effort. Remaining concerns are indicated below.

\(1\) General: There is a remaining concern that the authors don't adequately present how the current manuscript is a new and distinguished contribution relative to previous efforts. The added statement (along with the rest of the last paragraph) in the Introduction does not add any information. The reader will like to know what a "small section of the genome" means and why the authors logically stopped there the first time around as a study for publication. Likewise, the reader will want to see examples or classifications of what "other rat chromosome regions" corresponding to human GWAS genes are left to study and why. The first summary paragraph in the Discussion is not altogether convincing of a new contribution either. These boundaries among studies and respective manuscripts need to be clear, especially in light of apparently new contributions (e.g., PMID: 31584514) since original review of the current manuscript.

\(2\) General: Statements and supporting references need to be checked throughout the manuscript for validity. For example, there is a statement in the Introduction (Lines 65-66; "This difficulty...known to affect blood pressure) with citation of references that are approximately 7 years old now.

Reviewer \#2: Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) (Limit 100 to 20000 Characters)

Reviewer \#3: I congratulate Deng & Menard on their revision, and scientific efforts pertaining to the genetics of HTN. In this revision, they have addressed all comments. Their data is complex yet significant, and adds to their existing contribution to the literature. Higher resolution figures should be submitted.

Reviewer \#4: Deng and Menard present results of their continued work aiming to identify functional genetic variants related to blood pressure. In this particular study, they report on 3 QTLs present in DSS rats that map to numerous GWAS human genes linked to blood pressure. The authors also make the point that non-coding SNPs in GWAS act as markers of nearby QTLs rather than being QTLs themselves. Since functional genomics research lags behind the rate of statistically-based human GWAS, this work represents important findings and considerations. However, as noted by the previous reviewers, these authors recently have published a similar paper with the same overall messages. While new QTLs are discussed in the present manuscript, the Discussion of this manuscript has a degree of overlap with the Discussion of the J Hypert 2020 article (citation \#14).

1\. Although the authors modified the Introduction to state that the present analysis varied from the previous paper due to inclusion of other rat chromosome regions, I was left wondering if with this additional study a comprehensive set of the rat genome has now been evaluated by this group? How much more of the rat genome did the authors cover with this extension to the original work?

2\. Line 102 \"They are basically the same as documented previously \[15\].\" First, I believe the authors meant to cite reference 14 (not 15). Please verify. Second, this sentence would benefit from being rewritten. Stating that the methods were \"basically the same\" leaves one wondering if something was different and if so what? Please revise to provide clarity on how the methods differed, and if they did not differ, indicate that the methods were the same.

3\. The Discussion section is overly lengthly and has overlap with the original paper (citation 14). Particularly the material on noncoding GWAS SNPs serving as markers for nearby QTLs, a point that was discussed already at length in citation \#14. In this manuscript, I very much appreciated the thoughtful Discussion of missing heritability in GWAS and the omnigenic hypothesis. The Discussion needs to be condensed and so reducing content that is similar to the previous publication would shorten the section.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: Yes: Daiva Nielsen

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235756.r004

Author response to Decision Letter 1

4 May 2020

Reviewer \#1: Although some of my concerns have been sufficiently addressed while bringing up exciting questions for further study (regulation of endothelial-dependent vascular tone vs. regulation of systemic blood pressure), the revised presentation of the original manuscript appears to be a very modest effort. Remaining concerns are indicated below.

Response to Reviewer \#1 summary comment: We'd like thank you for recognizing our responses to your previous questions. It seems that you agree with scientific merits of our current work such as a major physiological effect from each QTL and a redundancy of multiple QTLs in their effects on blood pressure, modularity conservation between humans and rats, separation of SNP markers originating from primate evolution from functional genes nearby on blood pressure .

We are addressing your logistic concerns below. Also, we have added new phrases in Introduction as 'Here, we aimed at expanding the scope of rat QTL coverage to capture additional human GWAS genes in progressive stages, since we are a single investigator-driven lab. In the process, our new results have validated the reproducibility of our previous findings. We focused on distinct regions on DSS rat Chromosomes 7 and 8 that contain previously-unexplored rat blood pressure QTLs and human GWAS gene orthologs'. Hopefully, you are satisfied with them

Reviewer \#1 commment (1): There is a remaining concern that the authors don't adequately present how the current manuscript is a new and distinguished contribution relative to previous efforts. The added statement (along with the rest of the last paragraph) in the Introduction does not add any information. The reader will like to know what a "small section of the genome" means and why the authors logically stopped there the first time around as a study for publication. Likewise, the reader will want to see examples or classifications of what "other rat chromosome regions" corresponding to human GWAS genes are left to study and why. The first summary paragraph in the Discussion is not altogether convincing of a new contribution either. These boundaries among studies and respective manuscripts need to be clear, especially in light of apparently new contributions (e.g., PMID: 31584514) since original review of the current manuscript.

Response to Reviewer \#1 comment (1): We suspect that you were thinking of our current work as a partial overlap with our previous published work. You may wonder why we are submitting similar work on the genetics of other genome sections as a separate paper, instead of having all data put together as one publication. You wondered what justifications there is in presenting new data, but with similar conclusions.

You seem to think of our effort from the logistic stand point of view of GWASs, where hundreds of investigators were involved in consortia with thousands of supporting staff and a huge combined budget. That's why these GWASs were able to study associations from the whole genomes from multiple populations simultaneously, and published them as such. For example, reference 8 was able to present data on the entire genome, instead of portions of them. In contrast to this consortium-based research, our studies are individual-investigator based with one part-time research assistant supported by a tiny private fund. You may have noticed the authorship of 2 persons on the current manuscript and our previous publication.

Faced with the reality of limited resources, we have to comprehensively study QTLs from the entire rat genome corresponding to all human GWAS genes in progressive stages, and fragmented these studies over a long period of time as resources became available. At each stage, we focused on a few QTLs at a time, produced results only on these few QTLs as our resources allowed, analyzed them and sent them for publication. Once the validity of this limited work is peer-reviewed as legitimate and sound, we moved on to the next stage, once again with our very limited resources, to other regions of QTLs, only a few QTLs this second time. The result of second-stage studies used the same method. From this new work, we reproduced previous findings in different sections of the rat genome, and confirmed our previous conclusion. Another stage of investigations was repeated, so on and so forth.

As far as we know, our research lab with only 2 persons is the only one in the world doing this kind of work presented in the current manuscript. That is why the reproducibility of our findings is crucial to make our conclusions scientifically valid, as least in our hands. Unfortunately, there is no consortium on the physiology of QTLs in animal models at the present. Most of animal genetic researchers we know have moved on to 'greener pastures' of human GWAS.

As you may know, the scope of Plos One is to publish valid findings in science with sound methods. In our current manuscript, we do not claim to report the first finding in biologically capturing human GWAS genes with rat orthologs, which was reported in our previous publication (PMID: 31584514). Nevertheless, our current findings on different sections of rat genomes are methodologically sound, and novel in functionally capturing new human GWAS genes, which are different from our previous published results. This reproducibility and confirmation on our previous conclusions are necessary to move the field forward. Newly-identified candidates for different GWAS genes provide new entry point for further gene-targeting studies. Novel mechanistic insights of hypertension pathogenesis will follow.

You may be aware that even GWASs on blood pressure in human populations were published by same investigators in progressive stages in the past 11 years in high-impact journals such as Nature and Nature Genetics. Each of these incremental publications increased size and ethnicity, decreased minor allele frequencies of study populations from previous one, and also addressed the replicability issue in epidemiology.

In comparison, our physiological and functional studies of blood pressure QTLs do not need to increase the number of study subjects to be scientifically valid and to achieve sufficient power. This is because our hypertensive rat model and congenic knock in strains derived from it are inbred and homogeneous. They have been studied under a uniform environment. However, we do need to address the reproducibility issue. We have done so by analyzing different QTLs corresponding to different GWAS genes. As a result, our understanding of mechanisms of hypertension pathogenesis may have been improved with newly identified gene candidates responsible for different QTLs.

While we understand your comments on boundaries of results, we also like to bring your attention to our logistics and budgetary restraint of doing research in a 1-investigator-plus-one assistant lab. Just to let you know, we did not divide our results into separate publications, but rather we conducted and reported our progressive search from different stages and in an evolutionary time table. Based on our current work, we are planning further research, once again, in a small scale, in the future. We'll present our future results as they come. We'd appreciate your evaluation when the time comes.

\(2\) General: Statements and supporting references need to be checked throughout the manuscript for validity. For example, there is a statement in the Introduction (Lines 65-66; "This difficulty...known to affect blood pressure) with citation of references that are approximately 7 years old now.

Response to Reviewer \#1 comment (1): Yes, the reference is valid and the first GWAS reported on hypertension.

Reviewer \#2: Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) (Limit 100 to 20000 Characters)

Response to Reviewer \#2: There is no comments to respond to.

Reviewer \#3: I congratulate Deng & Menard on their revision, and scientific efforts pertaining to the genetics of HTN. In this revision, they have addressed all comments. Their data is complex yet significant, and adds to their existing contribution to the literature. Higher resolution figures should be submitted.

Response to Reviewer \#3 comment: Thank you for your appreciation. We have submitted our original figures in revision. Hopefully, the resolution is better.

Reviewer \#4: Deng and Menard present results of their continued work aiming to identify functional genetic variants related to blood pressure. In this particular study, they report on 3 QTLs present in DSS rats that map to numerous GWAS human genes linked to blood pressure. The authors also make the point that non-coding SNPs in GWAS act as markers of nearby QTLs rather than being QTLs themselves. Since functional genomics research lags behind the rate of statistically-based human GWAS, this work represents important findings and considerations. However, as noted by the previous reviewers, these authors recently have published a similar paper with the same overall messages. While new QTLs are discussed in the present manuscript, the Discussion of this manuscript has a degree of overlap with the Discussion of the J Hypert 2020 article (citation \#14).

Response to Reviewer \#4 summary comment: We thank you for your appreciation of our science in functional genomics research. The following will answer your concerns.

Reviewer \#4 comment (1). Although the authors modified the Introduction to state that the present analysis varied from the previous paper due to inclusion of other rat chromosome regions, I was left wondering if with this additional study a comprehensive set of the rat genome has now been evaluated by this group? How much more of the rat genome did the authors cover with this extension to the original work?

Response to Reviewer \#4 comment (1): We suspect that you were thinking of our current work as a partial overlap with our previous published work. You may wonder why we are submitting similar work on the genetics of other genome sections as a separate paper, instead of having all data put together as one publication. You wondered what justifications there is in presenting new data, but with similar conclusions.

You seem to think of our effort from the logistic stand point of view of GWASs, where hundreds of investigators were involved in consortia with thousands of supporting staff and a huge combined budget. That's why these GWASs were able to study associations from the whole genomes from multiple populations simultaneously, and published them as such. For example, reference 8 was able to present data on the entire genome, instead of portions of them. In contrast to this consortium-based research, our studies are individual-investigator based with one part-time research assistant supported by a tiny private fund. You may have noticed the authorship of 2 persons on the current manuscript and our previous publication.

Faced with the reality of limited resources, we have to comprehensively study QTLs from the entire rat genome corresponding to all human GWAS genes in progressive stages, and fragmented these studies over a long period of time as resources became available. At each stage, we focused on a few QTLs at a time, produced results only on these few QTLs as our resources allowed, analyzed them and sent them for publication. Once the validity of this limited work is peer-reviewed as legitimate and sound, we moved on to the next stage, once again with our very limited resources, to other regions of QTLs, only a few QTLs this second time. The result of second-stage studies used the same method. From this new work, we reproduced previous findings in different sections of the rat genome, and confirmed our previous conclusion. Another stage of investigations was repeated, so on and so forth.

As far as we know, our research lab with only 2 persons is the only one in the world doing this kind of work presented in the current manuscript. That is why the reproducibility of our findings is crucial to make our conclusions scientifically valid, as least in our hands. Unfortunately, there is no consortium on the physiology of QTLs in animal models at the present. Most of animal genetic researchers we know have moved on to 'greener pastures' of human GWAS.

As you may know, the scope of Plos One is to publish valid findings in science with sound methods. In our current manuscript, we do not claim to report the first finding in biologically capturing human GWAS genes with rat orthologs, which was reported in our previous publication (PMID: 31584514). Nevertheless, our current findings on different sections of rat genomes are methodologically sound, and novel in functionally capturing new human GWAS genes, which are different from our previous published results. This reproducibility and confirmation on our previous conclusions are necessary to move the field forward. Newly-identified candidates for different GWAS genes provide new entry point for further gene-targeting studies. Novel mechanistic insights of hypertension pathogenesis will follow.

You may be aware that even GWASs on blood pressure in human populations were published by same investigators in progressive stages in the past 11 years in high-impact journals such as Nature and Nature Genetics. Each of these incremental publications increased size and ethnicity, decreased minor allele frequencies of study populations from previous one, and also addressed the replicability issue in epidemiology.

In comparison, our physiological and functional studies of blood pressure QTLs do not need to increase the number of study subjects to be scientifically valid and to achieve sufficient power. This is because our hypertensive rat model and congenic knock in strains derived from it are inbred and homogeneous. They have been studied under a uniform environment. However, we do need to address the reproducibility issue. We have done so by analyzing different QTLs corresponding to different GWAS genes. As a result, our understanding of mechanisms of hypertension pathogenesis may have been improved with newly identified gene candidates responsible for different QTLs.

While we understand your comments, we also like to bring your attention to our logistics and budgetary restraint of doing research in a 1-investigator-plus-one assistant lab. Just to let you know, we did not divide our results into separate publications, but rather we conducted and reported our progressive search from different stages and in an evolutionary time table. Based on our current work, we are planning further research, once again, in a small scale, in the future. We'll present our future results as they come. We'd appreciate your evaluation when the time comes.

We have revised in the introduction to reflect my explanations to you above. 'Here, we aimed at expanding the scope of rat QTL coverage to capture additional human GWAS genes in progressive stages, since we are a single investigator-driven lab. In the process, our new results have validated the reproducibility of our previous findings. We focused on distinct regions on DSS rat Chromosomes 7 and 8 that contain previously-unexplored rat blood pressure QTLs and human GWAS gene orthologs.

Reviewer \#4 comment (2). Line 102 \"They are basically the same as documented previously \[15\].\" First, I believe the authors meant to cite reference 14 (not 15). Please verify. Second, this sentence would benefit from being rewritten. Stating that the methods were \"basically the same\" leaves one wondering if something was different and if so what? Please revise to provide clarity on how the methods differed, and if they did not differ, indicate that the methods were the same.

Response to Reviewer \#4 comment (2): Reference 15 is our original 'original' work on QTL modularity. Reference 14 used the same method as reference 15. Now we have added both references to avoid confusion. We have deleted 'basically' in the sentence to state that our current method is the same as reported in our previous work.

Reviewer \# 4 comment (3). The Discussion section is overly lengthly and has overlap with the original paper (citation 14). Particularly the material on noncoding GWAS SNPs serving as markers for nearby QTLs, a point that was discussed already at length in citation \#14. In this manuscript, I very much appreciated the thoughtful Discussion of missing heritability in GWAS and the omnigenic hypothesis. The Discussion needs to be condensed and so reducing content that is similar to the previous publication would shorten the section.

Response to Reviewer \#4 comment (3): You are right. We have deleted the similar discussion as we presented previously that you mentioned. We hope that the revised discussion is acceptable to you.
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Conserved mammalian modularity of quantitative trait loci revealed human functional orthologs in blood pressure control

PLOS ONE

Dear Dr. Deng,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The Reviewers finally agree that the manuscript deserves publication. I recommend that the remaining concerns pointed out by 2 of the 4 Referees are accounted for in view of the definitive acceptance of the paper.

Please submit your revised manuscript by Jul 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Alessandro Borri

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: N/A

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: TO THE AUTHORS:

PLOS One; PONE-D-19-35461.R2

Title: Conserved mammalian modularity of quantitative trait loci revealed human functional orthologs in blood pressure control

In response to my primary concern, the added information provided in the authors' responses and the statement in the Introduction (Lines 83-84; "We focused...Chromosomes 7 and 8...GWAS gene orthologs") may be sufficient for future readers.

As a note, the authors' responses could have been much more direct while simply stating what the new objective(s) is/are and that there is no significant overlap with previous efforts. The reviewer/reader shouldn't be left "wondering", "seeming to think", "hoping for" or "suspecting" anything when trying to understand a scientific study/manuscript. To the reasonable extent possible, a lucid presentation of a body of work as a scientific manuscript is an absolute requirement for publication per the responsibility of the authors. Off the record, limited laboratory staff/funding is indeed a frustrating experience and I wish the best of success for the authors in moving forward with their research. See below for a final suggestion for revising the manuscript.

\(1\) Introduction, Line 82: Remove "...since we are a single investigator-driven lab" from the sentence as that information is not germane to the objectives and findings of the study/manuscript.

Reviewer \#2: Thank you for addressing the comments.i don\'t have any comment further. The submission looks acceptable.

Reviewer \#3: The authors of the manuscript entitled conserved mammalian modularity of quantitative trait loci revealed human functional orthologs in blood pressure control have addressed my comments. The figures are better. I again congratulate Deng & Menard on their revision, and scientific efforts pertaining to the genetics of HTN. In this revision. Their data is complex yet significant, and adds to their existing contribution to the literature.

Reviewer \#4: Thank you for the clarification regarding the approach to your investigative program. The revision to the Introduction now clearly distinguishes the purpose of the present manuscript from the previous related work, and the revision to the Discussion reduces the overlap with the previous publication (ref \#14). I have only two minor requests remaining:

1\. Line 373: The word \"topics\" should be singular, revise to \"topic\".

2\. Somewhere in the text I would appreciate you noting that the rat has 21 chromosomes. This will help readers understand how much of the rat genome your work has covered and what is remaining.
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Dear Dr. Deng,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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